MUTATIONS IN LUNG CANCER WITH CLINICAL SIGNIFICANCE

Lung cancer is a complex and often fatal disease. The recent discoveries of activating mutations in EGFR and fusion genes involving ALK are milestones in a trend towards more personalized medicine in lung cancer. Targeting these alterations leads to survival benefit for our patients. EGFR and ALK testing can nowadays be considered as standard practice. Newer targets in the fight against lung cancer are discussed, such as MET and ROS.1 in adenocarcinoma. Also, new targets for squamous cell carcinoma are emerging, such as FGFR and DDR2.